Teachers Retirement System of The State of Kentucky Lowers Holdings in Abbott Laboratories $ABT

Posted by Francis Steltz on Jul 13th, 2026

Teachers Retirement System of The State of Kentucky lowered its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 5.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 234,451 shares of the healthcare product maker’s stock after selling 13,505 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Abbott Laboratories were worth $24,071,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the 4th quarter worth $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ABT shares. BTIG Research restated a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a report on Monday, April 27th. JPMorgan Chase & Co. lowered their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein cut their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Jefferies Financial Group reduced their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Evercore decreased their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $118.42.

Get Our Latest Stock Analysis on ABT

Abbott Laboratories Trading Up 0.0%

ABT opened at $93.97 on Monday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a market cap of $163.69 billion, a P/E ratio of 26.32, a PEG ratio of 1.62 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The business’s 50-day simple moving average is $89.21 and its 200-day simple moving average is $103.09.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.